Table 3.
Longitudinal clinical and biomarker outcomes of hyposmic PARS SAA participants.a
| Characteristic | SAA + Hyposmic (N = 34) | SAA- Hyposmic (N = 37) | Estimate (95% CI)b |
|---|---|---|---|
| Median change in UPDRS III score at 2-year visit (IQR)c | 0 (0–3) | 0 (−1 to 1) | 0d |
| Missing data | 4 | 4 | |
| Median change in UPDRS III score at 4-year visit (IQR)c | 2 (0–8) | 0 (−1 to 0) | 2.00 (−0.14 to 4.14) |
| Missing data | 14 | 19 | |
| DAT <70% at any visit — no. (%) | 12 (35) | 4 (11) | 3.26 (1.16–9.16) |
| Clinical Parkinsonism — no. (%)e | 8 (24) | 0 (0) | 18.46 (1.11–308.10) |
a
IQR denotes interquartile range.
b
Estimates (median differences for continuous measures, relative risks for categorical measures) and 95% confidence intervals have not been adjusted for multiplicity and should not be used in place of hypothesis testing.
c
Scores on part III of the Unified Parkinson’s Disease Rating Scale (UPDRS) range from 0 to 108, with higher scores indicating worse motor function.
d
For point estimates of 0, no confidence intervals are provided.
e
To compute the relative risk, 0.5 was added to all cells.